Immutep Limited has announced that they have achieved a 50% enrollment milestone in their TACTI-003 randomized Phase IIb trial for first line head and neck cancer treatment.
The trial is evaluating the company's first-in-class soluble LAG-3 protein 'eftilagimod alpha' in combination with MSD's anti-PD-1 therapy KEYTRUDA.
The trial is being conducted in 25 centers across the US, Australia and Europe and is expected to be fully recruited by mid-2023.
The IDMC recently reviewed initial safety and efficacy data and recommended continuing the trial without modifications.
HNSCC is the sixth most common cancer worldwide, with 890,000 new cases and 450,000 deaths reported in 2018.
Eftilagimod alpha has been granted Fast Track designation by the FDA for 1st line HNSCC, and is being evaluated for a variety of solid tumours, including NSCLC and HER2-/HR+ metastatic breast cancer.
Following the announcement, shares of Immutep (ASX:IMM) were unchanged at $0.28.